Additional Emotional and Economic Costs

Because women can present symptoms differently from men⁵ — which can contribute to vascular conditions being underdiagnosed and undertreated — more than half of women mention difficulty finding a doctor that takes them seriously, leading to a lack of trust, access and understanding for women and people of color.

Fallout from the emotional toll is exacerbated by economic burdens.

• In a single year, the incremental total medical costs per U.S. person with angina/chest pain were $14,796, with incremental cardiovascular-specific costs of $10,949.20. Additionally estimated annual costs due to absenteeism and presenteeism totaled per-person of $13,977.
  
• When this economic impact is applied across the estimated 1.5 million people with ischemia and no obstructive coronary artery disease (INOCA) among the U.S. workforce, the total estimated annual cost of lost productivity could be as high as $21 billion per year.⁴ With INOCA present in 50-70% of women,³ these costs can reach $10.5-$14.7 billion for women alone.

"Inherent biases can hinder a physician’s ability to detect and recognize symptoms, especially for populations that have been historically misdiagnosed in the cardiovascular disease setting, such as young, female and certain ethnicities," said Dr. Natalia Pinilla, Interventional Cardiologist at Hamilton Health Sciences/Niagara Health and Assistant Professor in the McMaster University Department of Medicine.

It's an emotional and economic toll that cannot be allowed to fester. At Abbott, we have a mission to restore dignity to healthcare through medical technology that’s affordable and accessible to help billions more by 2030. We understand that complex problems require multifaceted solutions to close these gaps in care for women and people of color.

Three Places to Start

• Enrolling more representative samples in clinical data studies, starting with more inclusive trial designs. Women account for only 38% of participants in cardiovascular clinical trials⁶ despite being half the U.S. population.⁷ For Black women, the numbers are even starker: 2.9% of participants in clinical pharmaceutical drug trials between 2006 and 2020,⁸ despite representing about 14% of the U.S. population,⁹ and whose age-adjusted rate of heart disease is 72% higher than for white women.¹⁰
• Leveraging comprehensive and inclusive data sets for training artificial intelligence (AI) algorithms, which are set to inform future diagnostic and therapy decisions for patients. "There are any number of ways that AI-based algorithms can, at their core, have bias," said Dr. David G. Armstrong, Professor of Surgery and Director of the Limb Preservation Program for the Keck School of Medicine at the University of Southern California. "We're trying to develop broad-based algorithms to allow deep learning instead of just being superficial and focusing on just one skin color. And we’re starting to see the results."
• Increasing investments in women’s health, incorporating the spectrum of clinical trials grant funding and ranging to Female Technology (FemTech) solutions that can help with disease management. As the number of women at the forefront of digital research continues to grow, it's important to recognize that FemTech is not a "side project." Women who feel they have been failed by clinicians are taking control of their own conditions and treatment options. "Female investors tend to better understand challenges in women's health space because chances are they have experienced them, too," said Marija Butkovic, LLM, Founder/CEO of Women of Wearables. "Diversifying their teams internally, as well as portfolios, institutional investors have the opportunity to not only democratize access to better healthcare for all but also to change the narrative around what good accessible healthcare means and technology is a big part of that."

Total Solution: Conscious Inclusion

To reduce the gender and race gaps with the help of digital health tools and screening technologies as well as computer-aided review of data, those tools would be most effective if they are truly programmed with diverse data sets that are representative of all populations,¹¹ requiring examination of personal biases in clinical and economic decision-making.

"The first step is to recognize physician and cultural bias in cardiovascular care and its socioeconomic and clinical impacts." said Dr. Nick West, Chief Medical Officer and Divisional Vice President of Medical Affairs, Abbott’s Vascular Business. "Only then can we begin to outline the necessary steps that must be taken to address the systemic issues underpinning underrepresentation, health inequity and ethnic/sex bias that are currently affecting patients suffering from vascular disease."

And that's the answer we all want to get to.